nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—Fluorouracil—urinary bladder cancer	0.132	0.551	CbGbCtD
Formoterol—CYP2C9—Fluorouracil—urinary bladder cancer	0.0454	0.19	CbGbCtD
Formoterol—CYP2C9—Cisplatin—urinary bladder cancer	0.0386	0.161	CbGbCtD
Formoterol—CYP2D6—Doxorubicin—urinary bladder cancer	0.0237	0.0987	CbGbCtD
Formoterol—CYP2C19—urine—urinary bladder cancer	0.00594	0.202	CbGeAlD
Formoterol—CYP2C9—urine—urinary bladder cancer	0.00461	0.157	CbGeAlD
Formoterol—CYP2D6—urine—urinary bladder cancer	0.00346	0.118	CbGeAlD
Formoterol—CYP2A6—prostate gland—urinary bladder cancer	0.00332	0.113	CbGeAlD
Formoterol—CYP2A6—seminal vesicle—urinary bladder cancer	0.00281	0.0956	CbGeAlD
Formoterol—ADRB1—prostate gland—urinary bladder cancer	0.00266	0.0908	CbGeAlD
Formoterol—CYP2A6—vagina—urinary bladder cancer	0.00164	0.0558	CbGeAlD
Formoterol—ADRB1—female reproductive system—urinary bladder cancer	0.00145	0.0495	CbGeAlD
Formoterol—CYP2C19—vagina—urinary bladder cancer	0.00105	0.0359	CbGeAlD
Formoterol—CYP2C9—female reproductive system—urinary bladder cancer	0.000903	0.0308	CbGeAlD
Formoterol—CYP2D6—renal system—urinary bladder cancer	0.000846	0.0288	CbGeAlD
Formoterol—CYP2D6—female reproductive system—urinary bladder cancer	0.000677	0.0231	CbGeAlD
Formoterol—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000634	0.00105	CcSEcCtD
Formoterol—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000633	0.00105	CcSEcCtD
Formoterol—Hypotension—Etoposide—urinary bladder cancer	0.000628	0.00104	CcSEcCtD
Formoterol—Gastritis—Doxorubicin—urinary bladder cancer	0.000628	0.00104	CcSEcCtD
Formoterol—Pain—Cisplatin—urinary bladder cancer	0.000627	0.00104	CcSEcCtD
Formoterol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000622	0.00103	CcSEcCtD
Formoterol—Dizziness—Thiotepa—urinary bladder cancer	0.000619	0.00102	CcSEcCtD
Formoterol—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000616	0.00102	CcSEcCtD
Formoterol—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000615	0.00485	CbGpPWpGaD
Formoterol—Urticaria—Fluorouracil—urinary bladder cancer	0.000615	0.00102	CcSEcCtD
Formoterol—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000613	0.00102	CcSEcCtD
Formoterol—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000613	0.00484	CbGpPWpGaD
Formoterol—Asthma—Doxorubicin—urinary bladder cancer	0.000613	0.00101	CcSEcCtD
Formoterol—Influenza—Doxorubicin—urinary bladder cancer	0.000613	0.00101	CcSEcCtD
Formoterol—CYP2A6—Biological oxidations—NAT2—urinary bladder cancer	0.000613	0.00483	CbGpPWpGaD
Formoterol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000612	0.00101	CcSEcCtD
Formoterol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000604	0.001	CcSEcCtD
Formoterol—Haematuria—Methotrexate—urinary bladder cancer	0.000602	0.000996	CcSEcCtD
Formoterol—Dyspnoea—Etoposide—urinary bladder cancer	0.000599	0.000992	CcSEcCtD
Formoterol—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000598	0.000989	CcSEcCtD
Formoterol—Somnolence—Etoposide—urinary bladder cancer	0.000597	0.000989	CcSEcCtD
Formoterol—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000597	0.000988	CcSEcCtD
Formoterol—Vomiting—Thiotepa—urinary bladder cancer	0.000595	0.000985	CcSEcCtD
Formoterol—Rash—Thiotepa—urinary bladder cancer	0.00059	0.000976	CcSEcCtD
Formoterol—Bronchitis—Doxorubicin—urinary bladder cancer	0.000589	0.000976	CcSEcCtD
Formoterol—Dermatitis—Thiotepa—urinary bladder cancer	0.000589	0.000975	CcSEcCtD
Formoterol—Headache—Thiotepa—urinary bladder cancer	0.000586	0.00097	CcSEcCtD
Formoterol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00058	0.00096	CcSEcCtD
Formoterol—Body temperature increased—Cisplatin—urinary bladder cancer	0.00058	0.00096	CcSEcCtD
Formoterol—Fatigue—Etoposide—urinary bladder cancer	0.000579	0.000959	CcSEcCtD
Formoterol—Pain—Etoposide—urinary bladder cancer	0.000575	0.000951	CcSEcCtD
Formoterol—Constipation—Etoposide—urinary bladder cancer	0.000575	0.000951	CcSEcCtD
Formoterol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000574	0.00095	CcSEcCtD
Formoterol—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000574	0.00095	CcSEcCtD
Formoterol—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000574	0.00453	CbGpPWpGaD
Formoterol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00057	0.000944	CcSEcCtD
Formoterol—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00057	0.000943	CcSEcCtD
Formoterol—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000569	0.00449	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000566	0.00446	CbGpPWpGaD
Formoterol—Asthenia—Gemcitabine—urinary bladder cancer	0.000565	0.000935	CcSEcCtD
Formoterol—Haematuria—Epirubicin—urinary bladder cancer	0.000563	0.000932	CcSEcCtD
Formoterol—Pharyngitis—Methotrexate—urinary bladder cancer	0.000562	0.000931	CcSEcCtD
Formoterol—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	0.000561	0.00443	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000561	0.00442	CbGpPWpGaD
Formoterol—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000559	0.000926	CcSEcCtD
Formoterol—Pruritus—Gemcitabine—urinary bladder cancer	0.000557	0.000922	CcSEcCtD
Formoterol—Nausea—Thiotepa—urinary bladder cancer	0.000556	0.00092	CcSEcCtD
Formoterol—Urethral disorder—Methotrexate—urinary bladder cancer	0.000555	0.000919	CcSEcCtD
Formoterol—Sinusitis—Epirubicin—urinary bladder cancer	0.000554	0.000917	CcSEcCtD
Formoterol—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000554	0.00437	CbGpPWpGaD
Formoterol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000554	0.000917	CcSEcCtD
Formoterol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000553	0.000915	CcSEcCtD
Formoterol—ADRB2—Arf6 signaling events—SRC—urinary bladder cancer	0.000552	0.00436	CbGpPWpGaD
Formoterol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000549	0.00091	CcSEcCtD
Formoterol—Pruritus—Fluorouracil—urinary bladder cancer	0.000547	0.000906	CcSEcCtD
Formoterol—Visual impairment—Methotrexate—urinary bladder cancer	0.000546	0.000904	CcSEcCtD
Formoterol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00054	0.000895	CcSEcCtD
Formoterol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000538	0.000891	CcSEcCtD
Formoterol—Urticaria—Etoposide—urinary bladder cancer	0.000534	0.000884	CcSEcCtD
Formoterol—Rhinitis—Epirubicin—urinary bladder cancer	0.000532	0.00088	CcSEcCtD
Formoterol—Abdominal pain—Etoposide—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Formoterol—Body temperature increased—Etoposide—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Formoterol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Formoterol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000531	0.000879	CcSEcCtD
Formoterol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000529	0.000876	CcSEcCtD
Formoterol—Asthenia—Cisplatin—urinary bladder cancer	0.000526	0.000871	CcSEcCtD
Formoterol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000526	0.000871	CcSEcCtD
Formoterol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000526	0.00087	CcSEcCtD
Formoterol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000524	0.000867	CcSEcCtD
Formoterol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000522	0.000865	CcSEcCtD
Formoterol—Haematuria—Doxorubicin—urinary bladder cancer	0.000521	0.000862	CcSEcCtD
Formoterol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000521	0.000862	CcSEcCtD
Formoterol—Urethral disorder—Epirubicin—urinary bladder cancer	0.00052	0.00086	CcSEcCtD
Formoterol—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000516	0.00407	CbGpPWpGaD
Formoterol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000513	0.000849	CcSEcCtD
Formoterol—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000512	0.00404	CbGpPWpGaD
Formoterol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000512	0.000847	CcSEcCtD
Formoterol—Dizziness—Fluorouracil—urinary bladder cancer	0.000512	0.000847	CcSEcCtD
Formoterol—Visual impairment—Epirubicin—urinary bladder cancer	0.000511	0.000846	CcSEcCtD
Formoterol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000511	0.000845	CcSEcCtD
Formoterol—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000509	0.00402	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000505	0.00398	CbGpPWpGaD
Formoterol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000502	0.000831	CcSEcCtD
Formoterol—Vomiting—Gemcitabine—urinary bladder cancer	0.0005	0.000828	CcSEcCtD
Formoterol—Mental disorder—Methotrexate—urinary bladder cancer	0.000496	0.000822	CcSEcCtD
Formoterol—Rash—Gemcitabine—urinary bladder cancer	0.000496	0.000821	CcSEcCtD
Formoterol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000496	0.000821	CcSEcCtD
Formoterol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000495	0.00082	CcSEcCtD
Formoterol—Malnutrition—Methotrexate—urinary bladder cancer	0.000493	0.000816	CcSEcCtD
Formoterol—Headache—Gemcitabine—urinary bladder cancer	0.000493	0.000816	CcSEcCtD
Formoterol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000492	0.000815	CcSEcCtD
Formoterol—Vomiting—Fluorouracil—urinary bladder cancer	0.000492	0.000814	CcSEcCtD
Formoterol—Rhinitis—Doxorubicin—urinary bladder cancer	0.000492	0.000814	CcSEcCtD
Formoterol—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	0.00049	0.00387	CbGpPWpGaD
Formoterol—Rash—Fluorouracil—urinary bladder cancer	0.000488	0.000808	CcSEcCtD
Formoterol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000487	0.000807	CcSEcCtD
Formoterol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000487	0.000806	CcSEcCtD
Formoterol—Headache—Fluorouracil—urinary bladder cancer	0.000485	0.000802	CcSEcCtD
Formoterol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000484	0.000802	CcSEcCtD
Formoterol—ADRB2—Arf6 signaling events—EGFR—urinary bladder cancer	0.000484	0.00382	CbGpPWpGaD
Formoterol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000483	0.0008	CcSEcCtD
Formoterol—Dysgeusia—Methotrexate—urinary bladder cancer	0.000483	0.000799	CcSEcCtD
Formoterol—Asthenia—Etoposide—urinary bladder cancer	0.000482	0.000798	CcSEcCtD
Formoterol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000482	0.000798	CcSEcCtD
Formoterol—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000481	0.000796	CcSEcCtD
Formoterol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000479	0.000793	CcSEcCtD
Formoterol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000478	0.000791	CcSEcCtD
Formoterol—Back pain—Methotrexate—urinary bladder cancer	0.000477	0.00079	CcSEcCtD
Formoterol—Pruritus—Etoposide—urinary bladder cancer	0.000475	0.000787	CcSEcCtD
Formoterol—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	0.000475	0.00375	CbGpPWpGaD
Formoterol—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000475	0.00375	CbGpPWpGaD
Formoterol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000474	0.000784	CcSEcCtD
Formoterol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000473	0.000783	CcSEcCtD
Formoterol—Nausea—Gemcitabine—urinary bladder cancer	0.000467	0.000774	CcSEcCtD
Formoterol—Vomiting—Cisplatin—urinary bladder cancer	0.000466	0.000772	CcSEcCtD
Formoterol—Mental disorder—Epirubicin—urinary bladder cancer	0.000464	0.000769	CcSEcCtD
Formoterol—Rash—Cisplatin—urinary bladder cancer	0.000462	0.000766	CcSEcCtD
Formoterol—Dermatitis—Cisplatin—urinary bladder cancer	0.000462	0.000765	CcSEcCtD
Formoterol—Malnutrition—Epirubicin—urinary bladder cancer	0.000462	0.000764	CcSEcCtD
Formoterol—Diarrhoea—Etoposide—urinary bladder cancer	0.00046	0.000761	CcSEcCtD
Formoterol—Nausea—Fluorouracil—urinary bladder cancer	0.00046	0.000761	CcSEcCtD
Formoterol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000458	0.000757	CcSEcCtD
Formoterol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000455	0.000754	CcSEcCtD
Formoterol—Tension—Epirubicin—urinary bladder cancer	0.000453	0.00075	CcSEcCtD
Formoterol—Dysgeusia—Epirubicin—urinary bladder cancer	0.000452	0.000748	CcSEcCtD
Formoterol—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	0.00045	0.00355	CbGpPWpGaD
Formoterol—Nervousness—Epirubicin—urinary bladder cancer	0.000448	0.000742	CcSEcCtD
Formoterol—Back pain—Epirubicin—urinary bladder cancer	0.000446	0.000739	CcSEcCtD
Formoterol—Malaise—Methotrexate—urinary bladder cancer	0.000445	0.000736	CcSEcCtD
Formoterol—Dizziness—Etoposide—urinary bladder cancer	0.000444	0.000736	CcSEcCtD
Formoterol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000444	0.000735	CcSEcCtD
Formoterol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000443	0.000733	CcSEcCtD
Formoterol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000442	0.000732	CcSEcCtD
Formoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000441	0.00348	CbGpPWpGaD
Formoterol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000438	0.000725	CcSEcCtD
Formoterol—Nausea—Cisplatin—urinary bladder cancer	0.000436	0.000721	CcSEcCtD
Formoterol—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000433	0.00342	CbGpPWpGaD
Formoterol—Cough—Methotrexate—urinary bladder cancer	0.00043	0.000712	CcSEcCtD
Formoterol—Mental disorder—Doxorubicin—urinary bladder cancer	0.00043	0.000711	CcSEcCtD
Formoterol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000428	0.000709	CcSEcCtD
Formoterol—Vomiting—Etoposide—urinary bladder cancer	0.000427	0.000707	CcSEcCtD
Formoterol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000427	0.000707	CcSEcCtD
Formoterol—Agitation—Epirubicin—urinary bladder cancer	0.000424	0.000702	CcSEcCtD
Formoterol—Rash—Etoposide—urinary bladder cancer	0.000424	0.000701	CcSEcCtD
Formoterol—Dermatitis—Etoposide—urinary bladder cancer	0.000423	0.000701	CcSEcCtD
Formoterol—Headache—Etoposide—urinary bladder cancer	0.000421	0.000697	CcSEcCtD
Formoterol—Myalgia—Methotrexate—urinary bladder cancer	0.00042	0.000695	CcSEcCtD
Formoterol—Arthralgia—Methotrexate—urinary bladder cancer	0.00042	0.000695	CcSEcCtD
Formoterol—Chest pain—Methotrexate—urinary bladder cancer	0.00042	0.000695	CcSEcCtD
Formoterol—Tension—Doxorubicin—urinary bladder cancer	0.000419	0.000694	CcSEcCtD
Formoterol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000418	0.000692	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000417	0.00069	CcSEcCtD
Formoterol—Malaise—Epirubicin—urinary bladder cancer	0.000416	0.000689	CcSEcCtD
Formoterol—Discomfort—Methotrexate—urinary bladder cancer	0.000415	0.000687	CcSEcCtD
Formoterol—Nervousness—Doxorubicin—urinary bladder cancer	0.000415	0.000687	CcSEcCtD
Formoterol—Back pain—Doxorubicin—urinary bladder cancer	0.000413	0.000684	CcSEcCtD
Formoterol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000411	0.00068	CcSEcCtD
Formoterol—Palpitations—Epirubicin—urinary bladder cancer	0.000408	0.000675	CcSEcCtD
Formoterol—Cough—Epirubicin—urinary bladder cancer	0.000403	0.000667	CcSEcCtD
Formoterol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000403	0.000666	CcSEcCtD
Formoterol—Infection—Methotrexate—urinary bladder cancer	0.0004	0.000662	CcSEcCtD
Formoterol—Nausea—Etoposide—urinary bladder cancer	0.000399	0.000661	CcSEcCtD
Formoterol—Hypertension—Epirubicin—urinary bladder cancer	0.000398	0.00066	CcSEcCtD
Formoterol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000396	0.000656	CcSEcCtD
Formoterol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000395	0.000653	CcSEcCtD
Formoterol—Chest pain—Epirubicin—urinary bladder cancer	0.000393	0.00065	CcSEcCtD
Formoterol—Myalgia—Epirubicin—urinary bladder cancer	0.000393	0.00065	CcSEcCtD
Formoterol—Arthralgia—Epirubicin—urinary bladder cancer	0.000393	0.00065	CcSEcCtD
Formoterol—Agitation—Doxorubicin—urinary bladder cancer	0.000392	0.00065	CcSEcCtD
Formoterol—Anxiety—Epirubicin—urinary bladder cancer	0.000392	0.000648	CcSEcCtD
Formoterol—Skin disorder—Methotrexate—urinary bladder cancer	0.000391	0.000647	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00039	0.000646	CcSEcCtD
Formoterol—Discomfort—Epirubicin—urinary bladder cancer	0.000388	0.000643	CcSEcCtD
Formoterol—Malaise—Doxorubicin—urinary bladder cancer	0.000385	0.000637	CcSEcCtD
Formoterol—Dry mouth—Epirubicin—urinary bladder cancer	0.000384	0.000636	CcSEcCtD
Formoterol—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.00038	0.003	CbGpPWpGaD
Formoterol—Palpitations—Doxorubicin—urinary bladder cancer	0.000377	0.000625	CcSEcCtD
Formoterol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000377	0.000624	CcSEcCtD
Formoterol—Oedema—Epirubicin—urinary bladder cancer	0.000377	0.000624	CcSEcCtD
Formoterol—Hypotension—Methotrexate—urinary bladder cancer	0.000376	0.000623	CcSEcCtD
Formoterol—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	0.000375	0.00296	CbGpPWpGaD
Formoterol—Infection—Epirubicin—urinary bladder cancer	0.000374	0.000619	CcSEcCtD
Formoterol—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.000374	0.00295	CbGpPWpGaD
Formoterol—Cough—Doxorubicin—urinary bladder cancer	0.000373	0.000617	CcSEcCtD
Formoterol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000369	0.000611	CcSEcCtD
Formoterol—Hypertension—Doxorubicin—urinary bladder cancer	0.000369	0.00061	CcSEcCtD
Formoterol—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000368	0.00291	CbGpPWpGaD
Formoterol—Tachycardia—Epirubicin—urinary bladder cancer	0.000368	0.000609	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000367	0.000607	CcSEcCtD
Formoterol—Skin disorder—Epirubicin—urinary bladder cancer	0.000366	0.000606	CcSEcCtD
Formoterol—Insomnia—Methotrexate—urinary bladder cancer	0.000364	0.000603	CcSEcCtD
Formoterol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000364	0.000602	CcSEcCtD
Formoterol—Chest pain—Doxorubicin—urinary bladder cancer	0.000364	0.000602	CcSEcCtD
Formoterol—Myalgia—Doxorubicin—urinary bladder cancer	0.000364	0.000602	CcSEcCtD
Formoterol—Anxiety—Doxorubicin—urinary bladder cancer	0.000362	0.0006	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000361	0.000598	CcSEcCtD
Formoterol—Discomfort—Doxorubicin—urinary bladder cancer	0.000359	0.000595	CcSEcCtD
Formoterol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000359	0.000594	CcSEcCtD
Formoterol—Somnolence—Methotrexate—urinary bladder cancer	0.000358	0.000592	CcSEcCtD
Formoterol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000356	0.000589	CcSEcCtD
Formoterol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000354	0.000586	CcSEcCtD
Formoterol—Hypotension—Epirubicin—urinary bladder cancer	0.000352	0.000583	CcSEcCtD
Formoterol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000349	0.000577	CcSEcCtD
Formoterol—Oedema—Doxorubicin—urinary bladder cancer	0.000349	0.000577	CcSEcCtD
Formoterol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000347	0.000575	CcSEcCtD
Formoterol—Fatigue—Methotrexate—urinary bladder cancer	0.000347	0.000574	CcSEcCtD
Formoterol—Infection—Doxorubicin—urinary bladder cancer	0.000346	0.000573	CcSEcCtD
Formoterol—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	0.000345	0.00272	CbGpPWpGaD
Formoterol—Pain—Methotrexate—urinary bladder cancer	0.000344	0.00057	CcSEcCtD
Formoterol—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000344	0.00271	CbGpPWpGaD
Formoterol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000343	0.000568	CcSEcCtD
Formoterol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000342	0.000566	CcSEcCtD
Formoterol—Insomnia—Epirubicin—urinary bladder cancer	0.000341	0.000564	CcSEcCtD
Formoterol—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000341	0.00269	CbGpPWpGaD
Formoterol—Tachycardia—Doxorubicin—urinary bladder cancer	0.00034	0.000563	CcSEcCtD
Formoterol—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000339	0.00267	CbGpPWpGaD
Formoterol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000339	0.00056	CcSEcCtD
Formoterol—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000336	0.00265	CbGpPWpGaD
Formoterol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000336	0.000556	CcSEcCtD
Formoterol—Somnolence—Epirubicin—urinary bladder cancer	0.000335	0.000554	CcSEcCtD
Formoterol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000332	0.000549	CcSEcCtD
Formoterol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000332	0.000549	CcSEcCtD
Formoterol—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000329	0.0026	CbGpPWpGaD
Formoterol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000329	0.000545	CcSEcCtD
Formoterol—Hypotension—Doxorubicin—urinary bladder cancer	0.000326	0.000539	CcSEcCtD
Formoterol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000325	0.000538	CcSEcCtD
Formoterol—Fatigue—Epirubicin—urinary bladder cancer	0.000325	0.000538	CcSEcCtD
Formoterol—Constipation—Epirubicin—urinary bladder cancer	0.000322	0.000533	CcSEcCtD
Formoterol—Pain—Epirubicin—urinary bladder cancer	0.000322	0.000533	CcSEcCtD
Formoterol—Urticaria—Methotrexate—urinary bladder cancer	0.00032	0.000529	CcSEcCtD
Formoterol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000318	0.000527	CcSEcCtD
Formoterol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000318	0.000527	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000318	0.000526	CcSEcCtD
Formoterol—Insomnia—Doxorubicin—urinary bladder cancer	0.000315	0.000522	CcSEcCtD
Formoterol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000311	0.000514	CcSEcCtD
Formoterol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00031	0.000514	CcSEcCtD
Formoterol—Somnolence—Doxorubicin—urinary bladder cancer	0.00031	0.000513	CcSEcCtD
Formoterol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000308	0.00051	CcSEcCtD
Formoterol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000307	0.000508	CcSEcCtD
Formoterol—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000303	0.00239	CbGpPWpGaD
Formoterol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000301	0.000498	CcSEcCtD
Formoterol—Fatigue—Doxorubicin—urinary bladder cancer	0.0003	0.000497	CcSEcCtD
Formoterol—Urticaria—Epirubicin—urinary bladder cancer	0.000299	0.000495	CcSEcCtD
Formoterol—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000299	0.00236	CbGpPWpGaD
Formoterol—Pain—Doxorubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Formoterol—Constipation—Doxorubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Formoterol—Abdominal pain—Epirubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Formoterol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000298	0.000493	CcSEcCtD
Formoterol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000297	0.000491	CcSEcCtD
Formoterol—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.00029	0.00229	CbGpPWpGaD
Formoterol—Asthenia—Methotrexate—urinary bladder cancer	0.000289	0.000478	CcSEcCtD
Formoterol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000287	0.000475	CcSEcCtD
Formoterol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000285	0.000472	CcSEcCtD
Formoterol—Pruritus—Methotrexate—urinary bladder cancer	0.000285	0.000471	CcSEcCtD
Formoterol—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000279	0.00221	CbGpPWpGaD
Formoterol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000278	0.000459	CcSEcCtD
Formoterol—Urticaria—Doxorubicin—urinary bladder cancer	0.000277	0.000458	CcSEcCtD
Formoterol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000276	0.000456	CcSEcCtD
Formoterol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000276	0.000456	CcSEcCtD
Formoterol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000275	0.000456	CcSEcCtD
Formoterol—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000275	0.00217	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000272	0.00215	CbGpPWpGaD
Formoterol—Asthenia—Epirubicin—urinary bladder cancer	0.00027	0.000447	CcSEcCtD
Formoterol—Pruritus—Epirubicin—urinary bladder cancer	0.000266	0.000441	CcSEcCtD
Formoterol—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000266	0.0021	CbGpPWpGaD
Formoterol—Dizziness—Methotrexate—urinary bladder cancer	0.000266	0.000441	CcSEcCtD
Formoterol—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000264	0.00208	CbGpPWpGaD
Formoterol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000258	0.000427	CcSEcCtD
Formoterol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000257	0.000425	CcSEcCtD
Formoterol—Vomiting—Methotrexate—urinary bladder cancer	0.000256	0.000424	CcSEcCtD
Formoterol—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000255	0.00201	CbGpPWpGaD
Formoterol—Rash—Methotrexate—urinary bladder cancer	0.000254	0.00042	CcSEcCtD
Formoterol—Dermatitis—Methotrexate—urinary bladder cancer	0.000254	0.00042	CcSEcCtD
Formoterol—Headache—Methotrexate—urinary bladder cancer	0.000252	0.000417	CcSEcCtD
Formoterol—Asthenia—Doxorubicin—urinary bladder cancer	0.00025	0.000414	CcSEcCtD
Formoterol—Dizziness—Epirubicin—urinary bladder cancer	0.000249	0.000412	CcSEcCtD
Formoterol—Pruritus—Doxorubicin—urinary bladder cancer	0.000247	0.000408	CcSEcCtD
Formoterol—Vomiting—Epirubicin—urinary bladder cancer	0.000239	0.000396	CcSEcCtD
Formoterol—Nausea—Methotrexate—urinary bladder cancer	0.000239	0.000396	CcSEcCtD
Formoterol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000238	0.000395	CcSEcCtD
Formoterol—Rash—Epirubicin—urinary bladder cancer	0.000238	0.000393	CcSEcCtD
Formoterol—Dermatitis—Epirubicin—urinary bladder cancer	0.000237	0.000393	CcSEcCtD
Formoterol—Headache—Epirubicin—urinary bladder cancer	0.000236	0.000391	CcSEcCtD
Formoterol—Dizziness—Doxorubicin—urinary bladder cancer	0.00023	0.000382	CcSEcCtD
Formoterol—Nausea—Epirubicin—urinary bladder cancer	0.000224	0.00037	CcSEcCtD
Formoterol—Vomiting—Doxorubicin—urinary bladder cancer	0.000222	0.000367	CcSEcCtD
Formoterol—Rash—Doxorubicin—urinary bladder cancer	0.00022	0.000364	CcSEcCtD
Formoterol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00022	0.000363	CcSEcCtD
Formoterol—Headache—Doxorubicin—urinary bladder cancer	0.000218	0.000361	CcSEcCtD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000216	0.0017	CbGpPWpGaD
Formoterol—Nausea—Doxorubicin—urinary bladder cancer	0.000207	0.000343	CcSEcCtD
Formoterol—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.000202	0.00159	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000201	0.00158	CbGpPWpGaD
Formoterol—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000198	0.00156	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000197	0.00155	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	0.000191	0.00151	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NAT1—urinary bladder cancer	0.000191	0.00151	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000185	0.00146	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000185	0.00146	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000183	0.00144	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000182	0.00144	CbGpPWpGaD
Formoterol—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000182	0.00144	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000181	0.00142	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	0.000175	0.00138	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.00017	0.00134	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000168	0.00133	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000167	0.00132	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000166	0.00131	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	0.000157	0.00124	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	0.000149	0.00117	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	0.000145	0.00114	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000132	0.00104	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	0.000129	0.00102	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000123	0.000971	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000117	0.000926	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000117	0.00092	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000117	0.00092	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—TYMP—urinary bladder cancer	0.000116	0.000914	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000115	0.000906	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000115	0.000905	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000113	0.000893	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000112	0.000885	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GLI1—urinary bladder cancer	0.000111	0.000875	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	0.000108	0.000856	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000107	0.000846	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000107	0.000846	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000107	0.000841	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000106	0.000839	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000106	0.000839	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NAT2—urinary bladder cancer	0.000105	0.000827	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000105	0.000825	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	9.81e-05	0.000774	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	9.72e-05	0.000767	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	9.6e-05	0.000758	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	9.07e-05	0.000715	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—RRM2—urinary bladder cancer	9.05e-05	0.000714	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—CXCL8—urinary bladder cancer	8.93e-05	0.000705	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	8.84e-05	0.000697	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	8.83e-05	0.000697	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	8.76e-05	0.000691	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	8.74e-05	0.00069	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ENO2—urinary bladder cancer	8.38e-05	0.000661	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	8.38e-05	0.000661	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	8.34e-05	0.000658	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	8.27e-05	0.000652	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	8.13e-05	0.000641	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	8.13e-05	0.000641	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	8.06e-05	0.000636	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RBX1—urinary bladder cancer	7.6e-05	0.0006	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	7.44e-05	0.000587	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TSC1—urinary bladder cancer	7.15e-05	0.000564	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.09e-05	0.000559	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TYMP—urinary bladder cancer	7.06e-05	0.000557	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	6.99e-05	0.000552	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JAG1—urinary bladder cancer	6.8e-05	0.000537	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.79e-05	0.000535	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NQO1—urinary bladder cancer	6.75e-05	0.000533	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	6.66e-05	0.000525	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TYMP—urinary bladder cancer	6.5e-05	0.000513	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.46e-05	0.00051	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TYMP—urinary bladder cancer	6.44e-05	0.000508	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NAT2—urinary bladder cancer	6.39e-05	0.000504	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.19e-05	0.000488	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NAT2—urinary bladder cancer	5.88e-05	0.000464	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.83e-05	0.00046	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—RHOA—urinary bladder cancer	5.75e-05	0.000454	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	5.63e-05	0.000444	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	5.63e-05	0.000444	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—RRM2—urinary bladder cancer	5.52e-05	0.000435	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—S100B—urinary bladder cancer	5.51e-05	0.000435	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	5.39e-05	0.000425	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—TYMS—urinary bladder cancer	5.24e-05	0.000413	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—RHOA—urinary bladder cancer	5.22e-05	0.000412	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	5.18e-05	0.000408	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	5.18e-05	0.000408	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	5.11e-05	0.000403	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	5.11e-05	0.000403	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ENO2—urinary bladder cancer	5.11e-05	0.000403	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.08e-05	0.000401	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.07e-05	0.0004	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.05e-05	0.000398	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.03e-05	0.000397	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GPX1—urinary bladder cancer	4.96e-05	0.000391	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.95e-05	0.000391	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NCOR1—urinary bladder cancer	4.95e-05	0.000391	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.94e-05	0.00039	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.88e-05	0.000385	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	4.87e-05	0.000384	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	4.85e-05	0.000382	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL2—urinary bladder cancer	4.83e-05	0.000381	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	4.72e-05	0.000372	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.7e-05	0.000371	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.7e-05	0.000371	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.66e-05	0.000367	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.66e-05	0.000367	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.63e-05	0.000365	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL8—urinary bladder cancer	4.59e-05	0.000362	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	4.57e-05	0.000361	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.56e-05	0.00036	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.52e-05	0.000356	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	4.49e-05	0.000354	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.45e-05	0.000351	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	4.38e-05	0.000346	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	4.37e-05	0.000344	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	4.29e-05	0.000338	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	4.27e-05	0.000337	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.12e-05	0.000325	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	4.01e-05	0.000316	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.99e-05	0.000315	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	3.92e-05	0.000309	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	3.89e-05	0.000307	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	3.81e-05	0.0003	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.79e-05	0.000299	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.75e-05	0.000296	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PPARG—urinary bladder cancer	3.71e-05	0.000293	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.64e-05	0.000287	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	3.56e-05	0.000281	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.48e-05	0.000275	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.43e-05	0.000271	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	3.41e-05	0.000269	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	3.37e-05	0.000266	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	3.35e-05	0.000264	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	3.34e-05	0.000263	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.32e-05	0.000262	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	3.29e-05	0.00026	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	3.28e-05	0.000259	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.19e-05	0.000252	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.18e-05	0.000251	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	3.17e-05	0.00025	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.16e-05	0.000249	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.16e-05	0.000249	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.16e-05	0.000249	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.13e-05	0.000247	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	3.1e-05	0.000244	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	3.09e-05	0.000243	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.03e-05	0.000239	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.02e-05	0.000238	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	3.02e-05	0.000238	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.97e-05	0.000234	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.94e-05	0.000232	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	2.92e-05	0.00023	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.91e-05	0.00023	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.9e-05	0.000229	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.9e-05	0.000229	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.88e-05	0.000227	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.88e-05	0.000227	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	2.86e-05	0.000225	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	2.79e-05	0.00022	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.79e-05	0.00022	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.78e-05	0.000219	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.76e-05	0.000217	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.73e-05	0.000215	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	2.71e-05	0.000214	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.71e-05	0.000213	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	2.69e-05	0.000212	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	2.65e-05	0.000209	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	2.63e-05	0.000208	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	2.59e-05	0.000204	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.56e-05	0.000202	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTEN—urinary bladder cancer	2.54e-05	0.000201	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.54e-05	0.000201	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	2.53e-05	0.0002	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	2.52e-05	0.000199	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	2.47e-05	0.000195	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	2.45e-05	0.000193	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.44e-05	0.000193	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	2.44e-05	0.000192	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—EP300—urinary bladder cancer	2.43e-05	0.000191	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	2.4e-05	0.000189	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.39e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	2.38e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	2.32e-05	0.000183	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	2.27e-05	0.000179	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.26e-05	0.000178	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	2.26e-05	0.000178	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	2.21e-05	0.000174	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.17e-05	0.000171	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.08e-05	0.000164	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.06e-05	0.000163	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	2.02e-05	0.00016	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2e-05	0.000158	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.98e-05	0.000156	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.98e-05	0.000156	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.98e-05	0.000156	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.94e-05	0.000153	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.87e-05	0.000148	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.83e-05	0.000144	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.78e-05	0.00014	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.66e-05	0.000131	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.64e-05	0.000129	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.63e-05	0.000128	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.62e-05	0.000128	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.59e-05	0.000125	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	1.56e-05	0.000123	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.55e-05	0.000122	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.48e-05	0.000117	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.43e-05	0.000113	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.41e-05	0.000112	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.36e-05	0.000107	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.35e-05	0.000106	CbGpPWpGaD
